

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Research Corporation Technologies, Inc.	05/30/2007

RECEIVING PARTY DATA

Name:	Novartis International Pharmaceutical Ltd.
Street Address:	Hurst Holme
Internal Address:	12 Trott Road
City:	Hamilton
State/Country:	BERMUDA
Postal Code:	HM 11

PROPERTY NUMBERS Total: 2

Property Type	Number
Application Number:	11848155
Application Number:	11981784

CORRESPONDENCE DATA

Fax Number: (952)876-4098
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: 9528764084
 Email: tjosephs@vhpglobalip.com
 Correspondent Name: Tanya K. Josephs
 Address Line 1: P.O. Box 111098
 Address Line 4: St. Paul, MINNESOTA 55111-1098

ATTORNEY DOCKET NUMBER:	17027.002US9&10
NAME OF SUBMITTER:	Tanya K. Josephs

Total Attachments: 3
 source=ASSIGNMT#page1.tif
 source=ASSIGNMT#page2.tif

CH \$80.00 11848155

501188466

**PATENT
 REEL: 024448 FRAME: 0587**

ASSIGNMENT OF PATENTS

"ASSIGNEE" means Novartis International Pharmaceutical Ltd., a Bermuda corporation with offices at Hurst Holme, 12 Trott Road, Hamilton HM 11, Bermuda.

"ASSIGNMENT AND LICENSE AGREEMENT" means the Assignment and License Agreement made effective as of May 29, 2007 between RCT and ASSIGNEE.

"DECA" means that certain Agreement for Disclosure, Evaluation and Commercialization of Inventions between RCT and INSTITUTION, effective September 23, 1996.

"INVENTOR" means Shohei Koide.

"INVENTIONS" means the inventions pertaining to Artificial Antibody Peptides and comprising the inventions that are the subject of the PATENT RIGHTS.

"INSTITUTION" means The University of Rochester.

"LICENSE AGREEMENT" means the License Agreement made effective July 1, 1999, as amended January 15, 2003 and May 2, 2007, between RCT and Adnexus Therapeutics, Inc. (as successor in interest to Phyllos, Inc.)

"PATENT RIGHTS" mean:

United States Patent No. 6462189, Issued 10/08/02
United States Patent No. 6703199, Issued 03/09/04
United States Patent No. 6673901, Issued 01/06/04
United States Patent No. 7078490, Issued 07/18/06
United States Patent No. 7119171, Issued 10/10/06
United States Patent No. 7153661, Issued 12/26/06
Australia Patent No. 729035, Issued 05/10/01
Japan Patent No. 3614866, Issued 11/12/04

United States Patent Application No. 11/410227, Filed 04/24/06
United States Patent Application No. 11/409939, Filed 04/24/06
Canada Patent Application No. 2293632, Filed 06/12/98
European Patent Application No. 98930131.2, Filed 06/12/98

"RCT" means Research Corporation Technologies, Inc., 101 North Wilmot Road, Suite 600, Tucson, Arizona 85711-3365.

1. BACKGROUND.

1.1. The INVENTOR made the INVENTIONS described in the PATENT RIGHTS and assigned his entire right, title and interest in the INVENTIONS and the PATENT RIGHTS to INSTITUTION.

1.2. Pursuant to the DECA, INSTITUTION assigned its entire right, title and interest in and to the INVENTIONS and the PATENT RIGHTS to RCT.

1.3. RCT thereafter licensed the INVENTIONS and the PATENT RIGHTS to Adnexus Therapeutics, Inc. (as successor in interest to Phyllos, Inc.) under the LICENSE AGREEMENT.

1.4. Pursuant to the ASSIGNMENT AND LICENSE AGREEMENT and this Assignment of Patents, RCT is assigning the INVENTIONS and the PATENT RIGHTS to ASSIGNEE, subject to the LICENSE AGREEMENT, on the following terms and conditions:

2. ASSIGNMENT

2.1. Pursuant and subject to the terms of the ASSIGNMENT AND LICENSE AGREEMENT, RCT hereby assigns to ASSIGNEE, and ASSIGNEE hereby takes and receives assignment of, RCT's entire right, title and interest in:

- (a) the INVENTIONS;
- (b) the PATENT RIGHTS and all foreign, divisional and continuation, in whole or in part, applications based on the PATENT RIGHTS;
- (c) all patents resulting from the applications described in the PATENT RIGHTS and otherwise described in (b) above; and
- (d) all reissues, extensions, renewals and reexaminations of the patents described in the PATENT RIGHTS and otherwise described in (c) above.

2.2. This assignment will allow ASSIGNEE to file the applications described in Paragraph 2.1 in its own name (but naming the INVENTOR as the inventor) in all countries of the world (where it is permissible) and the right to claim the benefit of the priority right provided by the International Convention of 1883, as amended.

2.3. RCT hereby authorizes and requests the United States Patent and Trademark Office and other national or regional patent offices throughout the world to issue to ASSIGNEE all patents described in Paragraph 2.1 that may be issued or granted.

2.4. RCT agrees to execute any further lawful documents that ASSIGNEE deems reasonably necessary to fully protect ASSIGNEE's interest in the INVENTION, the PATENT RIGHTS and the other items described in Paragraph 1.

2.5. RCT represents that it has not granted to anyone any right or license to use or practice under the PATENT RIGHTS, except (a) under this Assignment and the ASSIGNMENT AND LICENSE AGREEMENT, and (b) under the LICENSE AGREEMENT.

2.6. RCT represents that its right, title and interest in and to the PATENT RIGHTS have not been encumbered in any way, except (a) by this Assignment and the ASSIGNMENT AND LICENSE AGREEMENT, and (b) under the LICENSE AGREEMENT, and that no document that conflicts with this Assignment or the ASSIGNMENT AND LICENSE AGREEMENT has been or will be signed by RCT.

The Remainder Of This Page Intentionally Left Blank

RESEARCH CORPORATION TECHNOLOGIES, INC.

By: Shaun A. Kirkpatrick
Shaun A. Kirkpatrick
President & Chief Executive Officer


Date: 05/30/07

STATE OF ARIZONA)

COUNTY OF PIMA) ss.
)

On this 30 day of May, 2007, before me personally came Shaun A. Kirkpatrick, to me known to be the President and Chief Executive Officer of Research Corporation Technologies, Inc., the assignor named above, and acknowledged that he executed the foregoing instrument on behalf of the assignor and pursuant to authority duly received.

Mary Jo Rubasch
Notary Public



My Commission Expires: 07/27/10

NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.

By: Emil Bock
Name: EMIL BOCK
Title: MEMBER OF THE BOARD OF DIRECTORS

Date: 7/06/07

By: Michael Jones
Name: MICHAEL JONES
Title: EXECUTIVE


Date: 7th June 2007



On this 7 day of June, 2007, before me personally came EMIL BOCK AND MICHAEL JONES to me known to be the DIRECTORS of Novartis International Pharmaceutical Ltd., the assignee named above, and acknowledged that he executed the foregoing instrument on behalf of the assignee and pursuant to authority duly received, and he further acknowledged that the seal affixed to the foregoing instrument is the seal of the assignee and that it was affixed thereto pursuant to like authority.

M. Tonesan Amisshah
Notary Public

My Commission Expires: N/A



M. TONESAN AMISSAH
NOTARY PUBLIC
22 VICTORIA STREET
HAMILTON
BERMUDA